Literature DB >> 30335133

Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances.

T Valentin1, T Lesluyes2, S Le Guellec3, F Chibon3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30335133     DOI： 10.1093/annonc/mdy465

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).

Authors:  C Moreau-Bachelard; L Campion; M Toulmonde; A Le Cesne; M Brahmi; A Italiano; O Mir; S Piperno-Neumann; V Laurence; N Firmin; N Penel; F Duffaud; C Chevreau; F Bertucci; B Narciso; P Dubray-Longeras; C Delcambre; E Saada-Bouzid; P Boudou-Rouquette; P Soulie; C Perrin; J Y Blay; E Bompas
Journal:  ESMO Open       Date:  2022-02-21

2.  Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.

Authors:  Thomas Filleron; Sophie Le Guellec; Christine Chevreau; Bastien Cabarrou; Tom Lesluyes; Sabrina Lodin; Angélique Massoubre; Muriel Mounier; Muriel Poublanc; Frédéric Chibon; Thibaud Valentin
Journal:  BMC Cancer       Date:  2020-07-31       Impact factor: 4.430

3.  Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent.

Authors:  Ibtissam Acem; Merel M Smit; Cornelis Verhoef; Winan J van Houdt; Rick L Haas; Jos A van der Hage; Dirk J Grünhagen; Michiel A J van de Sande
Journal:  Ann Surg Oncol       Date:  2021-05-10       Impact factor: 5.344
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.